Menu
Search
|

Menu

Close
X

Heat Biologics Inc HTBX.OQ (NASDAQ Stock Exchange Capital Market)

2.34 USD
-- (--)
As of Jun 18
chart
Previous Close 2.34
Open --
Volume --
3m Avg Volume 237,430
Today’s High --
Today’s Low --
52 Week High 7.85
52 Week Low 1.09
Shares Outstanding (mil) 20.81
Market Capitalization (mil) 45.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-0.749
FY17
-4.741
FY16
-8.932
FY15
-25.217
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.18
Price to Sales (TTM)
vs sector
20.46
8.57
Price to Book (MRQ)
vs sector
1.74
4.35
Price to Cash Flow (TTM)
vs sector
--
22.78
Total Debt to Equity (MRQ)
vs sector
0.00
17.37
LT Debt to Equity (MRQ)
vs sector
0.00
12.92
Return on Investment (TTM)
vs sector
-172.54
13.17
Return on Equity (TTM)
vs sector
-204.56
15.15

EXECUTIVE LEADERSHIP

Jeffrey Wolf
Chairman of the Board, Chief Executive Officer, Since 2008
Salary: $404,583.00
Bonus: $202,500.00
Jeff Hutchins
Chief Operating Officer, Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
Ann Rosar
Vice President - Finance, Controller, Corporate Secretary, Since 2016
Salary: $152,386.00
Bonus: $40,000.00
John Prendergast
Independent Lead Director, Since 2017
Salary: --
Bonus: --
John Monahan
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

801 Capitola Dr
DURHAM   NC   27713-4382

Phone: +1919.2407133

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

SPONSORED STORIES